Aurobindo Pharma has informed that pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, a Meeting of the Board of Directors of the Company will be held on Thursday, February 6, 2020 to consider and approve Standalone & Consolidated Unaudited Financial Results of the Company for the third quarter and nine months period ended December 31, 2019 and payment of Second Interim Dividend, if any, for the financial year 2019•20. Further to its letter dated December 31, 2019 informing the closure of Trading Window of the Company from January 1, 2020 until 48 hours from the date of declaration of the Unaudited Financial Results of the Company for the third quarter ended December 31, 2019, the Trading Window will remain closed up to February 8, 2020 and shall be re-opened on February 9, 2020.
The above information is a part of company’s filings submitted to BSE.
